BIVI - BioVie Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0912
-0.0120 (-11.67%)
At close: 3:45PM EDT
Stock chart is not supported by your current browser
Previous Close0.1032
Open0.1000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0825 - 0.1100
52 Week Range0.0211 - 0.2500
Volume212,511
Avg. Volume153,849
Market Cap28.866M
Beta (3Y Monthly)3.01
PE Ratio (TTM)N/A
EPS (TTM)-0.0090
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire2 months ago

    BioVie Achieves Primary Objectives in Phase 2a Clinical Trial of BIV201 in Refractory Ascites

    The primary objectives of this initial open-label study were to assess the safety, tolerability, and steady state pharmacokinetics (PK) of terlipressin administered as a continuous infusion for 28 days to cirrhotic patients with refractory ascites.

  • GlobeNewswire2 months ago

    BioVie to Present at ThinkEquity Conference in NYC on May 2nd

    BioVie Inc. (BIVI) (“BioVie” or “Company”), a clinical-stage company developing innovative drug therapies for liver disease, announced that Mr. Terren Peizer, the Company’s Chairman and CEO, is scheduled to participate in the ThinkEquity Conference on May 2, 2019 in New York City. Event details: BioVie will present a company overview and clinical trial update on Thursday, May 2, 2019 at the Mandarin Oriental Hotel in New York City at 2:00 pm Eastern Time.

  • GlobeNewswire4 months ago

    BioVie Completes Patient Enrollment for its Phase 2a Clinical Trial of BIV201 in Refractory Ascites

    BioVie Inc. (BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for liver disease, announced today that it has completed enrollment in a Phase 2a open-label clinical study of BIV201 (continuous infusion terlipressin) in patients with refractory ascites due to advanced liver cirrhosis. “We are pleased to have achieved this important clinical milestone as we continue to develop BIV201 for patients with refractory ascites who are at high risk of deadly complications,” stated BioVie Chief Medical Officer Patrick Yeramian, MD. “What we have learned from this initial study is informing our next clinical trial design.

  • ACCESSWIRE7 months ago

    BioVie’s New Drug Candidate BIV201 Receives FDA Orphan Drug Designation for the Treatment of Hepatorenal Syndrome (HRS)

    LOS ANGELES, CA / ACCESSWIRE / November 28, 2018 / BioVie Inc. (BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for liver disease, announced today that the US Food and Drug Administration (FDA) has granted an Orphan Drug designation to BioVie for terlipressin for the treatment of hepatorenal syndrome (HRS). BIV201 is a new drug candidate currently being tested in a mid-stage (Phase 2a) clinical study in patients with refractory ascites due to advanced liver cirrhosis.